AQUESTIVE THERAPEUTICS INC (AQST)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AQST
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AQST | Director | 50 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Abigail L. Jenkins has served as a member of our Board of Directors since April 2024. Ms. Jenkins is an experienced biopharmaceutical executive and board director with more than 25 years of leadership experience across public and private biotechnology and pharmaceutical companies. Ms. Jenkins is currently an Entrepreneur in Residence with Duke University. Previously, Ms. Jenkins served as President and Chief Executive Officer and a member of the board of Gamida Cell Ltd. (Nasdaq:GMDA), a pioneer in cell therapies for patients with blood cancers, leading the company to its first product approval. Prior to joining Gamida Cell, Ms. Jenkins served as Chief Commercial and Business Officer at Lyndra Therapeutics, Inc., a clinical-stage biopharmaceutical company, where she established and led global commercial, business development, corporate strategy and portfolio management across multiple therapeutic areas. Ms. Jenkins also previously served on the board of XORTX Therapeutics, Inc. (Nasdaq:XRTX). Ms. Jenkins holds an M.S. in Biotechnology and Biotechnology Business Enterprise from The Johns Hopkins University, a B.A. in Psychology and Biology from Indiana University, and a certificate of achievement in General Management as a Kellogg Executive Scholar. Our Board believes that Ms. Jenkins extensive experience in the commercialization of pharmaceutical products, her business development and corporate strategy expertise and her experience in senior leadership roles across several biopharmaceutical companies qualifies her to serve on our Board of Directors.